English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/168460
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia

AuthorsÁlvarez-Twose, Iván; Martínez-Barranco, P.; Gotlib, Jason; García-Montero, Andrés ; Morgado, J. M.; Jara-Acevedo, Maria; Merker, J. D.; Peñalver, Francisco-Javier; Matito, Almudena; Hou, Y.; Sánchez-Muñoz, Laura; Mayado, Andrea; Mollejo, Manuela; Escribano, Luis; Orfao, Alberto
Issue Date2016
PublisherNature Publishing Group
CitationLeukemia 30(8): 1753-1756 (2016)
AbstractMast cell (MC) leukemia (MCL) is a subtype of systemic mastocytosis (SM) defined by the World Health Organization as ⩾ 20% of MCs in the bone marrow (BM) aspirate, with (leukemic variant) or without (aleukemic variant) ⩾ 10% of MCs in peripheral blood (PB). The European/American Consensus Group on Mastocytosis has recently proposed a new subclassification of MCL that distinguishes acute vs chronic MCL based on the presence vs absence of organ damage, respectively.
Identifiersdoi: 10.1038/leu.2016.30
e-issn: 1476-5551
issn: 0887-6924
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.